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Abstract 
Malaria is a life threatening infectious diseases transmitted by the bite of infected female Anopheles mosquito 
and responsible for high morbidity and mortality rates. Cerebral malaria is a complex neurological syndrome, 
whose pathology is mediated by inflammatory processes triggered by the immune system of the host following 
infection with Plasmodium falciparum. Coenzyme Q10 is an obligatory cofactor in the electron transport chain. 
The reduced form of Coenzyme Q10 serves as a potent antioxidant additionally; Coenzyme Q10 has been 
identified as a modulator of gene expression, inflammation and apoptosis. However, the modulatory effects of 
Coenzyme Q10 Plasmodium berghei ANKA infection process and risk occurrence of experimental cerebral 
malaria (ECM) have not been determined. The aim of this study was to elucidate the putative impact of oral 
administration of Coenzyme-Q10 on the initiation or regulation of inflammatory immune response in ECM of 
C57BL/6 mice during Plasmodium berghei ANKA (PbA) infection. We observed that oral administration of 
Coenzyme-Q10 both before and after PbA infection significantly hampered infiltration of inflammatory 
monocytes into the brain. Furthermore, pro-inflammatory cytokine TNF-α, which is associated with 
inflammation during ECM, was down-regulated in Coenzyme-Q10 administered mice. Remarkably, Coenzyme-
Q10 was very effective in inhibiting dendritic cell differentiation. These data collectively demonstrated the 
immuno-modulatory function of Coenzyme-Q10 on host inflammatory responses during ECM. 
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1. Introduction 
Malaria is considered a major health burden which continues to claim many lives globally; in 2017 
alone there were estimated 219 million cases and 435,000 related deaths, majority of these cases occurred in sub-
Saharan Africa (WHO, 2018). Malaria is transmitted by the bites of female anopheles mosquitoes; the major 
pathogens that are known to cause human disease include P. vivax, P. malariae, P. ovale, P. knowlesi and P. 
falciparum.  
The chief malaria complication is cerebral malaria which is caused by P. falciparum; and is a severe 
clinical neurological syndrome that affects pregnant women and children under the age of 5 years (WHO, 2016). 
Cerebral malaria (CM) is known to cause immune-mediated pathology due to sequestration of parasitized red 
blood cells in the micro-vasculature and overproduction of inflammatory mediators (Van der Heyde, 2006). 
However, despite treatment with current adjunct antimalarial drugs being in place, it is estimated that 15-25% 
children die of the disease (WHO, 2014). Moreover, it has been shown that children who survive from CM 
develop neurological sequelae, blindness and cognitive impairment (Mishra and Newton, 2009). This presents a 
big challenge to the management of CM. Despite the importance of the effects of the disease on the CNS, there 
are no projective diagnostics and treatments after onset of the disease. Furthermore, there is paucity of data on 
molecular events that contribute to the pathophysiology of the disease. 
The use of C57BL/6 mice as a mouse model of experimental cerebral malaria (ECM) is well 
documented; indeed this mouse model mimics many processes that occur in human cerebral malaria (White et 
al., 2010; de Souza et al., 2010). Notably, induction of pathology during ECM is linked to pro-inflammatory 
mediators (Scholfield and Grau, 2005). Specifically, dys-regulation of pro-inflammatory cytokine generation 
leads to tissue activation and generation of reactive oxygen species, with concomitant breakdown of the blood 
brain barrier that exacerbates the immune-pathological consequences (Angulo and Fresno, 2002). Nevertheless, a 
number of factors have complicated the understanding of pathophysiological events that leads to CM, this 
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includes rapid progression of the diseases in the presence of anti-malaria and relatively few cases of CM are 
reported. More importantly, CM due to P. falciparum infection can be prevented and treated. 
Coenzyme-Q10 is an important cofactor in the electron transport and uncoupling proteins (Echtay et al., 
2000). Moreover, Coenzyme-Q10 is a powerful antioxidant in both the mitochondria and lipid membranes. The 
potential impact of Coenzyme-Q10 on gene expression has been identified recently (Grneberg et al., 2005; Sabri 
et al., 2003; Schmelzer et al., 2009; Lee et al., 2004; Sohet et al., 2009).  
Accumulating evidence has shown that Coenzyme-Q10, attenuates neuro-inflammation in 
neurodegenerative diseases toxicity linked to drugs and immune cells (Nyariki et al., 2018; McCarthy et al., 
2004; Winkler et al., 2004). However, studies replicating effects of Coenzyme-Q10 on gene expression during 
experimental cerebral malaria are lacking. Thus, Coenzyme-Q10 appears to be a potent antioxidant to investigate 
as a potential alternative CM therapeutics on the pathologies that contribute to death in both ECM and CM. 
The anti-inflammatory functions of Coenzyme-Q10 especially its inhibitory effect on Nuclear factor 
kappa B and pro-inflammatory cytokines TNF-α and other mediator have prompted us to examine the role of 
Coenzyme-Q10 in experimental CM (ECM). In this paper, we investigated the putative impact of Coenzyme-
Q10 on ECM and showed that oral administration with Coenzyme-Q10 protected mice from ECM. Oral 
administration of Coenzyme-Q10 before and after PbA infection rescued mice from the occurrence of ECM. We 
demonstrate that the protective effect of Coenzyme-Q10 was through the inhibition of host associated pro-
inflammatory (IFN-g and TNF-α) and inflammatory monocytes coupled with reduction of dendritic cell 
maturation and differentiation. 
 
2. Materials and Methods 
2.1 Ethics statement and Mice 
This study utilized 3-4 weeks old C57BL/6J mice that were purchased from International Livestock 
Research Institute (ILRI). Approval of all experimental procedures and protocols involving mice were obtained 
from local regulatory agencies. All experimental procedures and protocols involving mice were reviewed and 
approved by Institutional review Committee (IRC) of Institute of Primate Research Karen, Kenya. The mice 
were maintained on mice pellets and water ad libitum at room temperature. Wood-chippings were provided as 
bedding material. 
2.2 Experimental design 
The mice were randomly divided into three groups each consisting of 5-6 mice. Group one was wild 
type (WT) naïve control, experimental group two: (WT + Coenzyme-Ql0 + PbA) and experimental group three: 
(Wild type + PbA alone). 
2.3 Plasmodium berghei ANKA infection studies 
All experiments in this study made use of Plasmodium berghei ANKA (Lundie et al., 2008). All 
experimental mice in group two and three were infected by intravenous (i.v) infection with 5x104 infected red 
blood cell (iRBC) that was obtained from a donor mice (stock mice) infected with stock solution of PbA, which 
was stored in liquid nitrogen as iRBC in solution containing 10% glycerol. Parasitaemia in infected mice was 
monitored daily with 5% Giemsa stained blood smears. 
2.3 Treatment of mice with 200mg/kg CoenzymeQ10  
Oral administration of 200mg/kg of Coenzyme-Q10 was done daily for one month prior to PbA 
infection to the experimental group two of mice. Administration of Coenzyme-Q10 was done using a gavage 
needle. Coenzyme-Q10 powder was prepared by directly dissolving it in olive oil. Coenzyme-Q10 was prepared 
immediately before use and the solution was protected from light before administration to the animals. 
2.4 Parasitaemia determination 
From day 2 post infection blood was collected daily from the tail vein and blood smears made. The 
blood slides were air dried and fixed in absolute methanol. Giemsa staining was made by mixing 1:20 Giemsa 
stock (Merck kGaA, Darmastadt Germany) and Giemsa buffer pH 7.2. Parasitemia levels were assessed by 
counting the number of visible parasites in 10 microscopic light fields and the percentage of iRBCs calculated 
(iRBCs/counted RBCs)* 100. 
2.5 Determination of Packed cell volume, body weight and haematological values 
Blood was either collected direct from the heart (during euthinization) for full haemogram analysis or 
from tail for packed cell volume (PCV) determination. Briefly blood was collected from the tail to heparinized 
capillary tubes which were then sealed with plasticin at one end. The sealed capillaries were centrifuged in a 
haematocrit centrifuge (Hawksley H England) at 10,000 RPM for five minutes. PCV was read using the micro-
haematocrit reader and expressed as percentage of the total blood volume. Full haemogram was analysed using 
automated Bechman Coulter counter. Body weight of each mouse was determined every two days using the 
analytical electronic balance (Mettler PM34, DoltaRange®). 
 
 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) DOI: 10.7176/JNSR 
Vol.9, No.2, 2019 
 
45 
2.6 Quantification of cytokine production by splenocytes 
 Mice were sacrificed on day 6 of ECM; the spleen was harvested followed by preparing the splenocyte 
culture according to Su et al., (2002). Briefly, the spleen organs from all the experimental treatment groups were 
harvested aseptically after which they were pressed through a sterile fine-wire mesh with RPMI 1640 medium 
together with 10% FCS. The splenocytes were then centrifuged at 350 X g for 10 min to make single cell 
suspensions. Erythrocytes were lysed with cold ammonium-chloride-Tris-buffer (ACT buffer) followed by 
washing the cells twice with fresh medium. Trypan blue was used to determine the splenocyte viability. 
Splenocyte were then adjusted to a final concentration of 10 million cells/ml in RPMI 1640 medium mixed with 
10% FCS buffer; aliquots of 200 µl of these cells were plated and incubated in 24-well flat-bottom tissue culture 
plates (Falcon) in triplicate for 24 h at 37°C in a humidified 5% CO2 incubator. Cytokines (IFN-g and TNF) in 
the culture supernatant and plasma samples were measured by ELISAs. 
2.7 Flow cytometry 
Mice were sacrificed at day 6 post infections, for flow cytometric measurement of inflammatory 
monocytes (Ly6C) and dendritic cells (DCs), 1.0x105 cells were re-suspended in 100 μl of FACS buffer and 
blocked with 2μl of human Fc-block (Sigma Aldrich). To the 96 well plate about 50μl/5x104 cells of the 
indicated master mix antibodies or appropriate isotype controls were added, gently mixed by vortexing and 
incubated on ice for 20 min. Additionally, single stained samples were prepared. For this purpose, a small part of 
each sample was taken and a cell master mix for the brain, liver and spleen cells was made in order to stain it 
with only one antibody. Thus a single stained sample for each antibody was created. The resulting cells were 
washed at least twice with FACS buffer by centrifugation followed by discarding the resulting supernatant, 
approximately 200 μl MACS buffer was added to the cells and then filtered using clean gauze in FACS tubes in 
order to remove any debris present. The cells were acquired and analyzed using the FACS LSR Fortessa of BD 
Biosciences. Then the data was analyzed with FACS Diva®/FlowJo software (Becton Dickinson).  
2.8 Statistical analysis 
One way ANOVA to compare treatment groups with controls Bonferronis post hoc tests was done for 
internal comparison. T-test was used to compare the percentage of Parasitemia levels. Results were given as 
mean± with significance set as p<0.05. The statistical analyses was done using Graphpad prism version 5 
software package. 
 
3.0 Results 
3.1 Coenzyme-Q10 administration has no effect on parasitaemia and general body weight  
during ECM  
The effect of Coenzyme-Q10 depends on the dosage and duration of administration. It was observed 
that blood parasitemia levels were not significantly changed in mice supplemented with Coenzyme-Q10 
compared with WT PbA-infected mice (Fig. 1A). This is consistent with other studies that demonstrated no 
correlation between blood parasitemia levels and survival from ECM (Dende et al., 2015; Gordon et al., 2015). 
The group of mice receiving Coenzyme-Q10 presented similar change in weight gain as WT infected mice (Fig. 
1B). 
Figure 1: No significant difference in parasitaemia percentage and weight among the treatment groups. 
(A) Parasitemia curve of WT-CoQ10-PbA and WT-PbA mice infected with P. berghei ANKA. (B) Weight curve 
of WT naïve, WT PbA and WTCoQ10-PbA mice. N=5-6 mice per group. 
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3.2 Coenzyme-Q10 supplemented mice have markedly reduced splenic myeloid and plasmocytoid 
conventional dendritic cells. 
Dendritic cells (DCs) play a decisive role that contributes to the events that shapes both the innate 
immunity and adoptive immune system. After they encounter the pathogen, DCs are activated to initiate and 
shape the immune responses. DCs are classified as either plasmocytoid dendritic cells (pDCs) or myeloid 
dendritic cells (mDCs). During infection with Plasmodium berghei, cDCs have been shown to induce CD4+ T 
cell activation. This study by deWalick ruled out the role of pDCs in pathogenesis of ECM. Previous study has 
also further showed that CD8α+DCs are the major APCs to CD8+T cells leading to priming and proliferation 
(Lundie, 2011). Therefore, the current study investigated whether supplementation of Coenzyme-Q10 influenced 
the DC phenotype during PbA infection. Splenic DCs were characterized first as CD11c+MHCII+CD3-CD19- and 
then further into CD8α+ and CD8αneg DCs. A decrease in the frequency and total count of mDCs in spleens of 
Coenzyme-Q10 supplemented PbA-infected mice was observed (Fig. 2A-B). Similarly, the frequency and 
percentage of pDCs in Coenzyme-Q10 supplemented mice was markedly reduced. (Fig. 2C-D).These data shows 
that Coenzyme-Q10 inhibits differentiation of splenic DCs during ECM. 
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Figure 2: Coenzyme-Q10 supplementation inhibited the expansion of splenic DC subsets 
The frequency of spleen CD11c+CD11b+ DCs (mDCs), and CD11c+B220+ DCs (pDCs) were analyzed by flow 
cytometry. Representative dot plots showing the proportions of brain mDCs and pDCs populations respectively 
(A- B). Bar graphs show the frequencies and absolute numbers of mDCs (C-D) and the frequencies and absolute 
numbers of pDCs populations within the brain. Data are presented as the mean ± SEM (n = 5- 6mice/group). 
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Results are representatives of three independent experiments. Percentage and total cell count of mDCs and pDCs 
values were compared by ANOVA, followed by a Bonferroni posttest (indicated level of significance: **P ≤ 
0.01; ***P ≤0.001). n=5-6 mice per group. 
 
3.3 The inflammatory monocyte levels are reduced in the brain of PbA-infected Coenzyme-Q10  
supplemented mice 
Infiltrated monocytes have been shown to play an important role in ECM pathogenesis settings 
(Schumak et al., 2015). Therefore, experiments were conducted to establish the functional significance of oral 
supplementation of Coenzyme-Q10 on the infiltration of inflammatory monocytes and neutrophils into the brain. 
Experimental mice in all groups were sacrificed at day 6 p.i. and brain cells associated lymphocytes were 
isolated.  The total number of inflammatory monocytes and neutrophil cells present in the brains of study 
animals were then quantified flow cytometrically, followed by calculating the percentage and absolute numbers 
of inflammatory monocytes. Infiltrated inflammatory monocytes and neutrophils were characterized as 
Ly6ChiLy6GnegCD11bhiCD45hi and Ly6GhiLy6CintCD11bhiCD45hi respectively (Fig. 3A). The percentage of 
brain inflammatory monocytes was significantly reduced in Coenzyme-Q10 supplemented mice in comparison 
with wild type PbA-infected mice (Fig. 3B). However, the frequency of neutrophil cells present in the brains of 
Coenzyme-Q10 supplemented and Wild type PbA-infected was comparable (Fig. 3C). Further investigations 
were done on the phenotype of the infiltrated inflammatory monocytes by looking at the expression of 
chemokine CCR-2 and adhesion molecule ICAM-1 on their surface. CCR-2 is an inflammatory chemokine with 
an important role in the recruitment of monocytes to the site of inflammation during infection (Schumak et al., 
2015). In comparison to the WT, the expression of CCR2 was decreased among the Coenzyme-Q10 
administered group (Fig. 3D). Similarly, an up-regulation of ICAM1 on inflammatory monocytes WT PbA, in 
comparison to Coenzyme-Q10 group was observed (Fig. 3E). 
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Figure 3: Low amount of inflammatory monocytes in Coenzyme-Q10 supplemented mice 
C57BL/6J mice were either un-supplemented or supplemented with Coenzyme-Q10 and then infected with 
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5x104 PbA iRBC. At day 6 of ECM, cellular infiltrates from the brains of individual mice were prepared and 
analysed by FACS. Flow cytometry gating scheme to identify inflammatory monocytes and neutrophil cells is 
shown for representative animals from WT infected (A) gMFI of (B) infiltrating 
monocytes (Ly6ChiLy6GnegCD11bhiCD45hi+);  of (C) Neutrophils (Ly6GhiLy6CintCD11bhiCD45hi); gMFI of (D) 
CCR2 on monocytes and gMFI of (E) ICAM1 on monocytes. Bars shows mean of each group ± SEM and are 
representative of at least two independent experiments. Percentage and gMFI of neutrophils, monocytes and its 
phenotypes was compared by ANOVA, followed by a Bonferroni posttest (indicated level of significance: *P ≤ 
0.05; **P ≤0.01;***P ≤0.001). n=5-6 mice per group. 
 
3.4 Coenzyme-Q10 supplementation abrogates pro-inflammatory cytokine profile at protein level 
The genesis of pathology during ECM is linked to immune-pathology component; and disruption of 
tight regulation of pro-inflammatory and anti-inflammatory cytokines are indicators of cerebral malaria 
progression (Angulo and Fresno, 2002). Therefore, an assessement was done to determine whether infected WT 
and Coenzyme-Q10 supplemented mice had differences in the concentration of pro-inflammatory at protein 
level. Mice that suffer from ECM symptoms have been shown to produce excessive amounts of pro-
inflammatory cytokines, and Coenzyme-Q10 supplemented mice were found to have markedly reduced serum 
levels of some of the pro-inflammatory cytokines (Fig. 4A–B). It was therefore, remarkable that Coenzyme-Q10 
supplementation provided some amelioration of inflammation in these mice.  
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Figure 4: Coenzyme-Q10 protected mice have modulated levels of splenocyte pro-inflammatory cytokines 
Indicated groups of mice were infected i.v. with 5x10e4 iRBC of PbA. Six days later, animals were sacrificed 
and the Spleens were isolated to prepare single cell suspensions. 1x10e6 splenocytes were cultured in vitro for 
24hr. Splenocytes were stimulated for 4hrs with PMA/Ionomycin in between.  Splenocyte concentrations of pro-
inflammatory cytokines (A-B) levels in the supernatant were analysed in the control groups and in PbA iRBC-
infected wt and Coenzyme-Q10 PbA-infected mice at d+6 p.i. Cytokine concentrations were determined by 
sandwich ELISA in the supernatants. Statistics= One Away ANOVA with Bonferroni posttest (indicated level of 
significance: *P ≤ 0.05; **P ≤0.01;***P ≤0.001). n=5-6 mice per group. 
 
4. Discussion 
We report for the first time that oral administration of Coenzyme-Q10 plays a key immune-modulatory 
role during ECM. Coenzyme-Q10 is a vital anti-oxidant with clinical application especially in the treatment of 
neurodegenerative and cardiovascular disorders (Spindler et al., 2009; McCarthy et al., 2004; Winkler et al., 
2004). Furthermore, previous studies have shown that Coenzyme-Q10 has the capacity to stimulate phagocytic 
activities and immune responses in rats and mice (Bliznakov et al., 1972). Thus, we were interested in 
elucidating the immune-modulatory role during ECM. 
 The Coenzyme-Q10 administered mice did not display any clinical symptoms associated with cerebral 
malaria, such as limb paralysis coma and convulsion. However, blood parasitemia levels were similar in mice 
supplemented with or without Coenzyme-Q10. This observation has been observed previously whereby there 
was no correlation between blood parasitemia levels and survival from ECM (Dende et al., 2015; Gordon et al., 
2015). Likewise, the group of mice receiving Coenzyme-Q10 presented similar change in weight gain as WT 
infected mice. 
 The indispensable role of infiltrated inflammatory monocytes in the development of immunopathology 
in ECM has been described (Schumak et al., 2015). Others have shown that inflammatory monocytes are critical 
in the control of blood-stage malaria due to P. chabaudi (Sponaas et al., 2009). This control of blood stage 
infection was reported to be mediated through the generation of ROS and iNOS by these monocytes (Sponaas et 
al., 2009). In this study, a reduction in brain inflammatory monocytes (Ly6ChiLy6GnegCD11bhiCD45hi) in 
Coenzyme-Q10 administered mice when compared to controls was observed. Findings from this study provide 
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compelling evidence that the direct reduction of infiltrated inflammatory monocytes into the brain may be 
responsible for the observed protection against ECM.  
Previously, it has been demonstrated that Ly6ChiCCR2pos inflammatory monocytes are critically 
involved in the initial stage of Plasmodium blood-stage infection (Schumak et al., 2015). Interestingly, the 
expression of CCR2 and ICAM-1 on monocytes was decreased in the Coenzyme-Q10 administered group. It is 
therefore possible that low levels of inflammatory monocytes and there phenotypes in Coenzyme-Q10 
administered mice contribute to reduction in brain inflammation, aiding in resistance to ECM pathology 
witnessed in this study. Nevertheless, inflammatory monocytes are co-producers of TNF-α in animal model of 
intracerebral hemorrhage (Hammond et al., 2014) and contact dermatitis (Chang and Nakrani, 2014); and are 
responsible for the recruitment of CD8+ T cells into the brain (Schumak et al., 2015). 
 Dendritic cells (DCs) are classified as either plasmocytoid dendritic cells (pDCs) or myeloid dendritic 
cells (mDCs). During infection with Plasmodium berghei, cDCs have been shown to induce CD4+ T cell 
activation, whereas pDCs in the pathogenesis of the ECM has been ruled out (He et al., 2014). Furthermore 
CD8α+DCs are the major antigen presenting cells to CD8+T cells leading to priming and proliferation (Lundie, 
2011). DCs are professional APCs that can also cross present antigens that can aggravate the development of 
ECM. We sought to determine whether supplementation of Coenzyme-Q10 could influence the DC phenotype 
during PbA infection. Importantly, there was a marked reduction in the accumulation of both mDCs and pDCs in 
the spleens of the Coenzyme-Q10 administered mice. These data shows that Coenzyme-Q10 either directly or 
indirectly interferes with differentiation of splenic DCs during ECM. These findings corroborate early 
observations showing that treatment of PbA-infected mice with vitamin D inhibits splenic DCs differentiation 
(He et al., 2014). 
 In a systematic review and meta-analysis, it was putatively demonstrated that exogenous administration 
of Coenzyme-Q10 significantly decreased genes for inflammation especially TNF-α levels (Zhai et al., 2017). A 
previous study working with Coenzyme-Q10 reported down-regulation of inflammatory markers associated with 
multiple sclerosis (Sanoobar et al., 2015). Additionally, in vitro studies demonstrated that Coenzyme-Q10 is a 
modulator of inflammatory gene expression (Schmelzer et al., 2007). Therefore, in view of the prominent 
inflammatory responses and antioxidant system failure due to plasmodium infections, employing compounds 
known to possess potent antioxidant and anti-inflammatory properties in ameliorating severity of the disease 
seemed logical. In the current investigation, augmentation of brain TNF-α and IFN-g inflammatory genes in 
PbA-infected mice was not surprising. Interestingly, Coenzyme-Q10 administered PbA-infected mice attenuated 
these inflammatory genes indicative of less inflammation in the brain of these mice. This was remarkable and 
first demonstration that Coenzyme-Q10 has the capacity to modulate inflammatory mediators associate with 
ECM protein level. 
Overall, the present study clearly demonstrated that diminished levels of inflammatory monocytes in 
the brains of Coenzyme-Q10 administered mice could also be an important factor for protection against 
inflammation. Moreover, Coenzyme-Q10 has the capacity inhibit dendritic cell differentiation and pro-
inflammatory cytokines TNF-α, thus protecting these mice against immune-induced inflammation. 
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